journal article·2025-04-14

Temperature-Controlled pNIB/PTX Micelles for Improved Paclitaxel Delivery in Ovarian Cancer Treatment

Ji-Hye Kang, Young-Jae Cho, Ji-Young Hwang, Sang-Yu Park, Jung-Joo Choi, E Sun Paik, Han-Sem Kim, Jeong-Won Lee, Ueon Sang Shin

Publisher page

Abstract

Paclitaxel (PTX) is a widely used anticancer drug for ovarian cancer treatment, but its clinical application is limited by poor water solubility and dose-limiting toxicities. To overcome these challenges, we developed a thermoresponsive, multistep drug delivery system, pNIB/PTX, designed to improve PTX solubility and provide controlled drug release. The pNIB/PTX-3 complex exhibited an initial rapid drug release phase followed by sustained slow release, optimizing both short-term and long-term therapeutic efficacy. At physiological temperatures, the complex demonstrated a precisely controlled drug release mechanism driven by changes in the polymeric micelle structure. In vitro studies showed that pNIB/PTX-3 significantly enhanced therapeutic effects in human ovarian cancer cell lines HeyA8 and SKOV3ip1, compared to PTX alone. In orthotopic ovarian cancer mouse models, a single intraperitoneal injection of pNIB/PTX-3 led to a substantial reduction in tumor size and prolonged survival. This multistep, thermoresponsive delivery system shows strong potential as a promising therapeutic option for dose-dense ovarian cancer treatments, providing improved drug stability, controlled release, and minimized side effects.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Mesoporous Materials and Catalysis · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Tissue Regeneration Engineering (ITREN), Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan 31116, Republic of Korea

Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea

Convergence Research Division, Korea Carbon Industry Promotion Agency (KCARBON), 110-11 Ballyong-ro, Deokjin-gu, Jeonju 54853, Republic of Korea

Department of Nano-biomedical Science BK21 FOUR NBM Global Research Center for Regenerative Medicine, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan 31116, Republic of Korea

Department of Obstetrics and Gynecology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Republic of Korea

Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea

Funding

National Research Foundation of Korea

References (59)

Show source-provided references
1. Howlader N. · 2020
2. 10.1056/NEJMoa05298510.1056/NEJMoa052985 ↗
3. 10.1007/s00280-017-3501-810.1007/s00280-017-3501-8 ↗
4. 10.1093/annonc/mds31510.1093/annonc/mds315 ↗
5. 10.1073/pnas.78.9.560810.1073/pnas.78.9.5608 ↗
6. 10.1021/bi00007a01410.1021/bi00007a014 ↗
7. 10.1158/1535-7163.MCT-13-079110.1158/1535-7163.MCT-13-0791 ↗
8. 10.1038/277665a010.1038/277665a0 ↗
9. 10.1091/mbc.10.4.94710.1091/mbc.10.4.947 ↗
10. 10.1080/0145974021407410.1080/01459740214074 ↗
11. 10.1016/j.jconrel.2005.09.03310.1016/j.jconrel.2005.09.033 ↗
12. 10.1002/ana.2495110.1002/ana.24951 ↗
13. Montaseri I. · 1997
14. 10.1073/pnas.90.20.955210.1073/pnas.90.20.9552 ↗
15. 10.1016/j.clon.2014.10.00110.1016/j.clon.2014.10.001 ↗
16. 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J ↗
17. 10.1007/s12156-010-0052-110.1007/s12156-010-0052-1 ↗
18. 10.1007/s11864-015-0338-410.1007/s11864-015-0338-4 ↗
19. 10.1016/S0140-6736(09)61157-010.1016/S0140-6736(09)61157-0 ↗
20. 10.1016/j.jtbi.2017.07.00310.1016/j.jtbi.2017.07.003 ↗
21. 10.1038/ncomms774410.1038/ncomms7744 ↗
22. 10.2147/IJN.S13197310.2147/IJN.S131973 ↗
23. 10.1016/j.jconrel.2019.08.03410.1016/j.jconrel.2019.08.034 ↗
24. 10.3389/fphar.2017.0100210.3389/fphar.2017.01002 ↗
25. 10.1038/s41467-017-00900-110.1038/s41467-017-00900-1 ↗
26. 10.1016/j.jconrel.2017.09.02610.1016/j.jconrel.2017.09.026 ↗
27. 10.3390/pharmaceutics1504120610.3390/pharmaceutics15041206 ↗
28. 10.1016/j.jddst.2023.10449410.1016/j.jddst.2023.104494 ↗
29. 10.1016/j.colsurfb.2023.11341910.1016/j.colsurfb.2023.113419 ↗
30. 10.2147/IJN.S39438310.2147/IJN.S394383 ↗
31. 10.1021/acsami.8b0812510.1021/acsami.8b08125 ↗
32. 10.1586/ecp.11.710.1586/ecp.11.7 ↗
33. 10.1016/S0168-3659(01)00275-910.1016/S0168-3659(01)00275-9 ↗
34. 10.1039/D1MA00961C10.1039/D1MA00961C ↗
35. 10.1016/j.ejps.2023.10652510.1016/j.ejps.2023.106525 ↗
36. 10.1016/j.jddst.2020.10152310.1016/j.jddst.2020.101523 ↗
37. 10.1515/ntrev-2021-006710.1515/ntrev-2021-0067 ↗
38. 10.2147/IJN.S15869610.2147/IJN.S158696 ↗
39. 10.1021/acs.jpclett.5b0173910.1021/acs.jpclett.5b01739 ↗
40. 10.1039/C4RA03736G10.1039/C4RA03736G ↗
41. 10.3390/pharmaceutics1408163610.3390/pharmaceutics14081636 ↗
42. 10.1016/j.addr.2020.09.00910.1016/j.addr.2020.09.009 ↗
43. 10.18632/oncotarget.531910.18632/oncotarget.5319 ↗
44. 10.1021/acs.chemrev.9b0077410.1021/acs.chemrev.9b00774 ↗
45. 10.1039/C5PY00998G10.1039/C5PY00998G ↗
46. 10.1039/C5RA13557E10.1039/C5RA13557E ↗
47. 10.1021/ma402391a10.1021/ma402391a ↗
48. 10.1002/agt2.1210.1002/agt2.12 ↗
49. 10.1039/c2sm25285f10.1039/c2sm25285f ↗
50. 10.1021/acs.bioconjchem.6b0070410.1021/acs.bioconjchem.6b00704 ↗
51. 10.1021/jp910417g10.1021/jp910417g ↗
52. 10.1021/am501422r10.1021/am501422r ↗
53. 10.1021/acsami.6b0382010.1021/acsami.6b03820 ↗
54. Horwitz S. · Ann. Oncol · 1994 · 5 · S310.1093/annonc/5.suppl_4.S3 ↗
55. 10.1186/s11658-019-0164-y10.1186/s11658-019-0164-y ↗
56. 10.1038/s41467-024-49512-610.1038/s41467-024-49512-6 ↗
57. 10.1038/s41598-019-41941-410.1038/s41598-019-41941-4 ↗
58. 10.3109/0265204900902183210.3109/02652049009021832 ↗
59. 10.1245/s10434-010-1028-x10.1245/s10434-010-1028-x ↗